meloxicam sold brand name mobic among others nonsteroidal antiinflammatory medication nsaid used treat pain inflammation rheumatic diseases used mouth injection recommended used short period possible low common side effects include abdominal pain dizziness swelling headache serious side effects may include heart disease stroke kidney problems stomach use recommended third trimester blocks blocks oxicam family chemicals closely related meloxicam patented approved medical use united states developed boehringer ingelheim however also available generic commonly prescribed medication united states million intravenous version meloxicam anjeso approved medical use united states february meloxicam use result gastrointestinal toxicity bleeding headaches rash dark black stool sign intestinal bleeding fewer gastrointestinal side effects perhaps nsaids october us food drug administration fda required drug label updated nonsteroidal antiinflammatory medications describe risk kidney problems unborn babies result low amniotic recommend avoiding nsaids pregnant women weeks later like nsaids use associated increased risk cardiovascular events heart attack although meloxicam inhibits formation thromboxane appear levels would interfere platelet pooled analysis randomized controlled studies meloxicam therapy days duration found meloxicam associated statistically significantly lower number thromboembolic complications nsaid diclofenac versus respectively similar incidence thromboembolic events naproxen people hypertension high cholesterol diabetes risk cardiovascular side effects people family history heart disease heart attack stroke tell treating physician potential serious cardiovascular side effects nsaids cause increase risk serious gastrointestinal adverse events including bleeding ulceration perforation stomach intestines fatal elderly patients greater risk serious gastrointestinal recommended withhold meloxicam use least four six halflives prior surgical dental procedures due increased risk taste perversion ulcerative stomatitis dry mouthmedical citation needed meloxicam blocks cyclooxygenase cox enzyme responsible converting arachidonic acid prostaglandin first step synthesis prostaglandins mediators inflammation meloxicam shown especially low therapeutic doses selectively inhibit meloxicam concentrations synovial fluid range plasma free fraction synovial fluid times higher plasma due lower albumin content synovial fluid compared plasma significance penetration may account fact performs exceptionally well treatment arthritis animal bioavailability meloxicam decreased administered orally compared equivalent iv bolus dose different oral formulations meloxicam use oral meloxicam following highfat breakfast increases mean peak drug levels however manufacturer make specific meal recommendations addition use antacids show pharmacokinetic chronic dosing time maximum plasma concentration following oral administration approximately mean volume distribution meloxicam approximately l highly proteinbound mainly meloxicam extensively metabolized liver enzymes minor four inactive metabolites peroxidase activity thought responsible two remaining meloxicam predominantly excreted form metabolites occurs equal extents urine traces unchanged parent drug found urine mean elimination halflife ranges use meloxicam recommended people peptic ulcer disease increased gastrointestinal bleed risk including years age taking medications associated bleeding adverse events found dosedependent associated length meloxicam used veterinary medicine treat also sees offlabel use animals cattle common side effects include gastrointestinal irritation vomiting diarrhea healthy dogs given meloxicam perioperative adverse effects cardiovascular system reported recommended perioperative administration meloxicam cats affect postoperative respiratory rate heart peerreviewed journal article cites nsaids including meloxicam causing gastrointestinal upset high doses acute kidney injury cns signs seizures comas cats adds cats low tolerance decline renal excretory function observed meloxicam administered cats chronic kidney disease cats received meloxicam greater proteinuria months cats received placebo concluded meloxicam used caution cats chronic kidney meloxicam investigated alternative diclofenac royal society protection birds rspb prevent deaths dogs absorption meloxicam stomach affected presence peak concentration cmax meloxicam occurring blood hours halflife meloxicam approximately hours koala phascolarctos cinereus little meloxicam absorbed blood oral administration poor meloxicam approved us use dogs management pain inflammation associated osteoarthritis oral liquid formulation january product insert added warning boldface type use injectable formulation use dogs approved us food drug administration fda november october formulation use cats approved use prior surgery injectable meloxicam indicated single onetime dose specific repeated warnings administer second fda sent notice violation manufacturer promotional materials included promotion drug offlabel february meloxicam injection approved use united states fda granted approval anjeso baudax europe product licensed antiinflammatory benefits including relief acute chronic pain dogs meloxicam also licensed use horses relieve pain associated musculoskeletal meloxicam authorised use cattle throughout european union january via centralised marketing first generic meloxicam product approved june meloxicam registered longterm use cats australia new zealand united kingdom meloxicam licensed use cats guinea pigs horses livestock including pigs cattle httpsenwikipediaorgwikimeloxicam